Interventions to combat or prevent drug counterfeiting: A systematic review

BMJ Open

Volumn 5, Issue 3, 2015, Pages

  El Jardali, Fadi ^a,b   Akl, Elie A ^a,b   Fadlallah, Racha ^a   Oliver, Sandy ^c   Saleh, Nadine ^d   El Bawab, Lamya ^a   Rizk, Rana ^e   Farha, Aida ^a   Hamra, Rasha ^f  

^a AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

^b MCMASTER UNIVERSITY   (Canada)

^c UNIVERSITY OF LONDON   (United Kingdom)

^d LEBANESE UNIVERSITY   (Lebanon)

^e MAASTRICHT UNIVERSITY   (Netherlands)

^f MINISTRY OF PUBLIC HEALTH   (Lebanon)

Author keywords

[No Author keywords available]

Indexed keywords

COUNTERFEIT DRUG;

CLINICAL TRIAL (TOPIC); CONCEPTUAL FRAMEWORK; CONSUMER; DRUG COUNTERFEITING; DRUG MARKETING; DRUG PACKAGING; HEALTH CARE; HOSPITAL DEPARTMENT; HUMAN; MEDICATION ERROR; META ANALYSIS; OUTCOMES RESEARCH; PREVALENCE; PUBLIC-PRIVATE PARTNERSHIP; RANDOMIZED CONTROLLED TRIAL (TOPIC); REGISTRATION; REVIEW; RISK ASSESSMENT; SYSTEMATIC REVIEW; UNLICENSED DRUG USE; FRAUD; HEALTH CARE POLICY; INTERNATIONAL COOPERATION; LEGISLATION AND JURISPRUDENCE; PHARMACY; PREVENTION AND CONTROL; PUBLIC HEALTH; STATISTICS AND NUMERICAL DATA;

COUNTERFEIT DRUGS; FRAUD; HEALTH POLICY; HUMANS; INTERNATIONAL COOPERATION; PHARMACEUTICAL SERVICES, ONLINE; PUBLIC HEALTH;

EID: 84926443338     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2014-006290     Document Type: Review

References (53)

1. Mackey TK, Liang BA. Improving global health governance to combat counterfeit medicines: a proposal for a UNODC-WHO-Interpol trilateral mechanism. BMC Med 2013;11:233.
2. World Health Organization. General information on counterfeit medicines. http://www.who.int/medicines/services/counterfeit/overview/en/ (accessed 7 Mar 2014). Secondary World Health Organization. General information on counterfeit medicines.
3. [No authors listed]. Fighting fake drugs: the role of WHO and pharma. Lancet 2011;377:1626.
4. World Health Organization. Medicines: spurious/falsely-labelled/falsified/counterfeit (SFFC) medicines. 2012. http://www.who.int/mediacentre/factsheets/fs275/en/ (accessed 25 Mar 2014).
5. Putze E, Conway E, Reilly M, et al. The Deadly World of Fake Drugs. http://www.aei.org/files/2012/02/27/-appendix-a-master-2-170026856632.pdf (accessed 3 Apr 2014).
6. Faucon B. No cure for fake drugs. The Wall Street Journal 15 February 2010. http://online.wsj.com/news/articles/SB10001424052748704533204575047282075703998 (accessed 3 April 2014).
7. Liberman J. Combating counterfeit medicines and illicit trade in tobacco products: minefields in global health governance. J Law Med Ethics 2012;40:326-47.
8. Degardin K, Roggo Y, Margot P. Understanding and fighting the medicine counterfeit market. J Pharm Biomed Anal 2014;87:167-75.
9. Newton PN, Amin AA, Bird C, et al. The primacy of public health considerations in defining poor quality medicines. PLoS Med 2011;8:e1001139.
10. World Health Organization. Substandard/spurious/falsely-labelled/falsified/counterfeit medical products: report of the Working Group of Member States. 2012. http://apps.who.int/gb/ebwha/pdf-files/WHA65/A65-23-en.pdf (accessed 20 Mar 2014).
11. Attaran A, Barry D, Basheer S, et al. How to achieve international action on falsified and substandard medicines. BMJ 2012;345:e7381.
12. Liang BA. Fade to black: importation and counterfeit drugs. Am J Law Med 2006;32:279-323.
13. Kelesidis T, Kelesidis I, Rafailidis PI, et al. Counterfeit or substandard antimicrobial drugs: a review of the scientific evidence. J Antimicrob Chemother 2007;60:214-36.
14. Cockburn R, Newton PN, Agyarko EK, et al. The global threat of counterfeit drugs: why industry and governments must communicate the dangers. PLoS Med 2005;2:e100.
15. World Health Organization. Counterfeit medicines. 2006. http://www. who.int/medicines/services/counterfeit/impact/ImpactF-S/en/ (accessed 21 Nov 2014).
16. World Health Organization. Counterfeit drugs kill! 2008. http://www.who.int/impact/FinalBrochureWHA2008a.pdf (accessed 28 Mar 2014).
17. Bansal D, Malla S, Gudala K, et al. Anti-counterfeit technologies: a pharmaceutical industry perspective. Sci Pharm 2013;81:1-13.
18. Bigdeli M, Javadi D, Hoebert J, et al., Alliance for Health Policy and Systems Research Network of Researchers on Access to Medicines. Health policy and systems research in access to medicines: a prioritized agenda for low- and middle-income countries. Health Res Policy Syst 2013;11:37.
19. World Health Organization. Medicines: spurious/falsely-labelled/falsified/counterfeit (SFFC) medicines. Fact sheet N 275. 2012. http://www.who.int/mediacentre/factsheets/fs275/en/
20. Higgins J, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. http://handbook.cochrane.org/ (accessed 8 Apr 2014).
21. Borenstein M, Hedges LV, Higgins JPT, et al. A basic introduction to fixed-effect and random-effects models for meta-analysis. Res Synth Method 2010;1:97-111.
22. Sterne JA, Sutton AJ, Ioannidis JP, et al. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ 2011;343:d4002.
23. Syhakhang L, Lundborg CS, Lindgren B, et al. The quality of drugs in private pharmacies in Lao PDR: a repeat study in 1997 and 1999. Pharm World Sci 2004;26:333-8.
24. Abdoulaye I, Chastanier H, Azondekon A, et al. Evaluation of a public awareness campaigns on counterfeit medicines in Cotonou, Benin. Med Trop (Mars) 2006;66:615-18.
25. World Health Organization. Survey of the quality of selected antimalarial medicines circulating in six countries of sub-Saharan Africa 2011 Jan. http://apps.who.int/medicinedocs/documents/s19053en/s19053en.pdf (accessed 21 Mar 2014).
26. Bate R, Jensen P, Hess K, et al. Substandard and falsified anti-tuberculosis drugs: a preliminary field analysis. Int J Tuberc Lung Dis 2013;17:308-11.
27. Bate R, Jin GZ, Mathur A. Does price reveal poor-quality drugs? Evidence from 17 countries. J Health Econ 2011;30:1150-63.
28. Khan MH, Okumura J, Sovannarith T, et al. Counterfeit medicines in Cambodia - possible causes. Pharm Res 2011;28:484-9.
29. Wondemagegnehu E. Counterfeit and Substandard Drugs in Myanmar and Viet Nam. 1999. http://apps.who.int/medicinedocs/pdf/s2276e/s2276e.pdf (accessed 24 Apr 2014).
30. Bate R, Hess K. The role of pre-shipment batch testing in ensuring good medicine quality. Malar World J 2012;3. http://www.aei.org/wpcontent/uploads/2012/12/-bate-the-role-of-preshipment-batch-testing-in-ensuring-good-medicine-quality-12150071370.pdf
31. World Health Organization. Survey of the quality of anti-tuberculosis medicines circulating in selected newly independent states of the former Soviet Union. November 2011. http://apps.who.int/medicinedocs/documents/s19053en/s19053en.pdf?ua=1 (accessed 23 Apr 2014).
32. Evans L, III, Coignez V, Barojas A, et al. Quality of anti-malarials collected in the private and informal sectors in Guyana and Suriname. Malar J 2012;11:203.
33. Hadi U, van den Broek P, Kolopaking EP, et al., Study Group Antimicrobial Resistance in Indonesia: Prevalence and Prevention AMRIN. Cross-sectional study of availability and pharmaceutical quality of antibiotics requested with or without prescription (Over The Counter) in Surabaya, Indonesia. BMC Infect Dis 2010;10:203.
34. Phanouvong S, Raymond C, Krech L, et al. The quality of antimalarial medicines in western Cambodia: a case study along the Thai-Cambodian border. Southeast Asian J Trop Med Public Health 2013;44:349-62.
35. Tipke M, Diallo S, Coulibaly B, et al. Substandard anti-malarial drugs in Burkina Faso. Malar J 2008;7:95.
36. Lon CT, Tsuyuoka R, Phanouvong S, et al. Counterfeit and substandard antimalarial drugs in Cambodia. Trans R Soc Trop Med Hyg 2006;100:1019-24.
37. USP Drug Quality and Information Program. Survey of the Quality of Selected Antimalarial Medicines Circulating in Madagascar, Senegal, and Uganda, 2010. http://docs.mak.ac.ug/reports/survey-quality-selected-antimalarial-medicines-circulating-madagascar-senegal-and-uganda (accessed 27 Feb 2014).
38. Bate R, Mathur A. The impact of improved detection technology on drug quality: a case study of Lagos, Nigeria. AEI Economic Policy Working Paper, 2011. http://www.aei.org/wp-content/uploads/2011/10/Nigeria-Working-Paper-v1.pdf (accessed 2 Apr 2014).
39. Newton PN, Fernandez FM, Plancon A, et al. A collaborative epidemiological investigation into the criminal fake artesunate trade in South East Asia. PLoS Med 2008;5:e32.
40. Promoting the Quality of Medicines Program. Strengthening national capacity in medicines quality: five-year summary (2005-2009) promoting the quality of medicines program in Southeast Asia and the Philippines. Rockville, MD: The United States Pharmacopeial Convention, 2010. http://www.usp.org/worldwide/dqi/resources/technicalReports.html (accessed 24 Mar 2014).
41. Krech LA, Barlow CL, Siv L, et al. Cambodian ministry of health takes decisive actions in the fight against substandard and counterfeit medicines. Trop Med Surg 2014;2. http://esciencecentral.org/journals/cambodian-ministry-of-health-takes-decisive-actions-in-the-fight-against-substandard-and-2329-9088.1000166.pdf
42. Pribluda VS, Barojas A, Anez A, et al. Implementation of basic quality control tests for malaria medicines in Amazon Basin countries: results for the 2005-2010 period. Malar J 2012;11:202.
43. Ministry of Health, Food and Drug Department (MOH, FDD). Country Report on Medicines Quality Monitoring Program in Laos (2005-2009). 2010. http://www.usp.org/app/worldwide/medQualityDatabase/download.php?id=20 (accessed 24 Mar 2014).
44. Guyatt GH, Oxman AD, Kunz R, et al. GRADE guidelines: 7. Rating the quality of evidence - inconsistency (accessed 23 Nov 2014). J Clin Epidemiol 2011;64:1294-302.
45. Lau J, Ioannidis JP, Terrin N, et al. The case of the misleading funnel plot. BMJ 2006;333:597-600.
46. World Health Organization. Growing threat from counterfeit medicines. Bull World Health Organ 2010;88:247-8.
47. Williams A. Europe prepares to battle the counterfeiters. Pharm Technol Eur 2011;23:9-11.
48. Almuzaini T, Choonara I, Sammons H. Substandard and counterfeit medicines: a systematic review of the literature. BMJ Open 2013;3:e002923.
49. Nayyar GM, Breman JG, Newton PN, et al. Poor-quality antimalarial drugs in southeast Asia and sub-Saharan Africa. Lancet Infect Dis 2012;12:488-96.
50. Karunamoorthi K. The counterfeit anti-malarial is a crime against humanity: a systematic review of the scientific evidence. Malar J 2014;13:209.
51. Kovacs S, Hawes SE, Maley SN, et al. Technologies for detecting falsified and substandard drugs in low and middle-income countries. PLoS ONE 2014;9:e90601.
52. Coustasse A, Arvidson C, Rutsohn P. Pharmaceutical counterfeiting and the RFID technology intervention. J Hosp Mark Public Relations 2010;20:100-15.
53. Pribluda VS, Barojas A, Coignez V, et al. The three-level approach: a framework for ensuring medicines quality in limited-resource countries. Pharmaceut Reg Affairs 2014;3:117.